Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
30 12 2021
Historique:
received: 25 03 2021
accepted: 26 07 2021
pubmed: 20 8 2021
medline: 15 1 2022
entrez: 19 8 2021
Statut: ppublish

Résumé

Intracranial hemorrhage (ICH) is a severe complication that is relatively common among patients with hemophilia. This systematic review aimed to obtain more precise estimates of ICH incidence and mortality in hemophilia, which may be important for patients, caregivers, researchers, and health policy makers. PubMed and EMBASE were systematically searched using terms related to "hemophilia" and "intracranial hemorrhage" or "mortality." Studies that allowed calculation of ICH incidence or mortality rates in a hemophilia population ≥50 patients were included. We summarized evidence on ICH incidence and calculated pooled ICH incidence and mortality in 3 age groups: persons of all ages with hemophilia, children and young adults younger than age 25 years with hemophilia, and neonates with hemophilia. Incidence and mortality were pooled with a Poisson-Normal model or a Binomial-Normal model. We included 45 studies that represented 54 470 patients, 809 151 person-years, and 5326 live births of patients with hemophilia. In persons of all ages, the pooled ICH incidence and mortality rates were 2.3 (95% confidence interval [CI], 1.2-4.8) and 0.8 (95% CI 0.5-1.2) per 1000 person-years, respectively. In children and young adults, the pooled ICH incidence and mortality rates were 7.4 (95% CI, 4.9-11.1) and 0.5 (95% CI, 0.3-0.9) per 1000 person-years, respectively. In neonates, the pooled cumulative ICH incidence was 2.1% (95% CI, 1.5-2.8) per 100 live births. ICH was classified as spontaneous in 35% to 58% of cases. Our findings suggest that ICH is an important problem in hemophilia that occurs among all ages, requiring adequate preventive strategies.

Identifiants

pubmed: 34411236
pii: S0006-4971(21)01481-6
doi: 10.1182/blood.2021011849
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2853-2873

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 by The American Society of Hematology.

Auteurs

Anne-Fleur Zwagemaker (AF)

Department of Pediatric Hematology, Emma Children's Hospital, and.

Samantha C Gouw (SC)

Department of Pediatric Hematology, Emma Children's Hospital, and.

Julie S Jansen (JS)

Department of Pediatric Hematology, Emma Children's Hospital, and.

Caroline Vuong (C)

Department of Pediatric Hematology, Emma Children's Hospital, and.

Michiel Coppens (M)

Department of Vascular Medicine-Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.

Qun Hu (Q)

Department of Pediatrics, Tongji Hospital, Tongji Medical University, Wuhan, China.

Xiaoqin Feng (X)

Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Soon K Kim (SK)

Department of Pediatrics, Inha University Hospital, Incheon, Korea; and.

Johanna G Van der Bom (JG)

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden University, Leiden, The Netherlands.

Karin Fijnvandraat (K)

Department of Pediatric Hematology, Emma Children's Hospital, and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH